The International Market Analysis Research and Consulting Group is a leading adviser on management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, chemicals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
IMARC’s tailored approach combines unfathomable insight into the dynamics of companies and markets with close cooperation at all levels of the client organization. This ensures that our clients achieve unmatchable competitive advantage, build more proficient organizations, and secure lasting results.
According to the latest report by IMARC Group, titled “ Systemic Lupus Erythematosus (SLE) Drugs Market: Global Industry Trends, Share, Size, Growth, Oppo rtunity and Forecast 2023-2028
” the global systemic lupus erythematosus (SLE) drugs market reached a strong growth in 2022.
Systemic lupus erythematosus (SLE) is an autoimmune medical condition characterized by protean clinical manifestations, multisystem inflammation (MIS), and a relapsing and remitting course (RRMS). It affects numerous parts of the body, including the skin, joints, kidneys, and brain. It is generally caused due to various genetic, environmental, and hormonal factors. Its symptoms include fatigue, joint pain and swelling, headache, rashes, hair loss, anemia, blood clotting, and fever. SLE is diagnosed by a healthcare provider using symptom assessments, physical examinations, chest X-rays, urinalysis, and blood tests. Its symptoms can be eased using anti-inflammatory drugs for joint pain and stiffness, steroid creams for rashes, corticosteroids to minimize the immune response, and antimalarial drugs for skin problems. It also uses disease-modifying drugs and targeted immune system agents for more severe cases. Besides this, it is treated using various immunosuppressive drugs that inhibit the activity of the immune system.
Request Free Sample Report:
https://www.imarcgroup.com/systemic-lupus-erythematosus-drugs-market/requestsample
The increasing prevalence of autoimmune diseases among individuals and the rising number of patients suffering from SLE represents one of the major factors driving the demand for SLE drugs around the world. Moreover, the rising number of research and diagnostics institutes are undertaking measures and introducing public awareness campaigns to educate individuals about SLE and its possible treatments. In addition, governments and non-governmental organizations (NGOs) of numerous countries are investing in various programs to develop novel therapeutics and identify relevant drug targets for the treatment of SLE. This, coupled with the increasing financing to improve healthcare infrastructure and diagnostic technologies worldwide, is impelling the market growth. Apart from this, the easy availability of various generic drugs for relieving pain, inflammation, and stiffness associated with SLE through offline and online retail channels is favoring the market growth. They generally involve over the counter (OTC) and prescription-based nonsteroidal anti-inflammatory drugs (NSAIDs), such as aspirin, ibuprofen (Motrin), naproxen, celecoxib (Celebrex), diclofenac (Voltaren), diflunisal (Dolobid), and piroxicam (Feldene). Furthermore, the increasing use of Hydroxychloroquine drugs is contributing to the market growth. Besides this, the growing awareness among individuals and healthcare professionals about the benefits of early diagnosis and treatment of SLE is influencing the overall sales of SLE drugs.
Looking forward, the market value is projected to reach a strong growth during the forecast period (2023-2028).
Market Summary:
Drug Class Insights:
• Antimalarials Drugs
• Chloroquine
• Hydroxychloroquine
• Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
• Cytotoxic and Immunosuppressive Drugs
• Cyclophosphamide
• Methotrexate
• Mycophenolate Mofetil
• Tacrolimus
• Cyclosporine
• Biologics
• Others
Mode of Delivery Insights:
• Intravenous
• Subcutaneous
• Oral
Regional Insights:
• North America
• United States
• Canada
• Asia-Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa
Note: We are updating our reports, If you want latest primary and secondary data (2023-2028) with Cost Module, Business Strategy, Distribution Channel, etc. Click request free sample report.
Aurinia Pharmaceuticals Inc.
GSK plc and ImmuPharma Plc. Kindly note that this only represents a partial list of companies and the complete list has been provided in the report.Kindly note that this only represents a partial list of companies
• the complete list has been provided in the report
View Full Report with TOC & List of Figure:
https://www.imarcgroup.com/systemic-lupus-erythematosus-drugs-market
We are the trusted business partners to the world's leading corporates, governments, and institutions
We are the trusted business partners to the world's leading corporates, governments, and institutions
© 2019 IMARC All Rights Reserved
This Publication and all it’s contents unless otherwise mentioned are copyrighted in the name of International Market Analysis Research and Consulting (IMARC). No part of this publication may be reproduced, repackaged, redistributed or resold in whole or in any part. The publication may also not be used in any form or by and means graphic electronic or mechanical, including photocopying, recording, taping or by information storage or retrieval, or by any other form, without the express consent of International Market Analysis Research and Consulting (IMARC).
Disclaimer: All contents and data of this publication, including forecasts, data analysis and opinion have been based on information and sources believed to be accurate and reliable at the time of publishing. International Market Analysis Research and Consulting makes no representation of warranty of any kind as to the accuracy or completeness of any Information provided. IMARC accepts no liability whatsoever for any loss or damage resulting from opinion, errors or inaccuracies if any found this publication.
IMARC, IMARC Group and Global Therapy Insight Series are registered trademarks of International Market Analysis Research and Consulting. All other trademarks used in this publication are registered trademarks of their respective companies.
